Search
for
Sort by
Research 121–150 of 1000+
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Alopecia – New building blocks
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- Annual Convention in the Time of COVID
- Studi Molecular Docking Aktivitas Anti Alopecia pada Senyawa yang Terkandung dalam Daun Dadap Serep (Erythrina subumbrans (Hassk.) Merrill)
- Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
- Novel investigational drugs for alopecia areata and future perspectives
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Advances in the mechanism and new therapies of alopecia areata
- Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Pattern hair loss distribution: a novel presentation for alopecia areata
- <i>JAMA Dermatology—</i>The Year in Review, 2021
- Treatment Challenges in Alopecia Areata: Insights From a Case of Baricitinib Therapy Failure
- THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
- Ann Robinson’s research reviews —12 May 2022
- Alopecia areata
- Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
- Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Evidence for the off-label use of tofacitinib in alopecia areata
- Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Novedades terapéuticas en tricología
- Alopecia Areata and Systemic Lupus Erythematosus: Insights From a Nationwide Case–Control Study